<DOC>
	<DOCNO>NCT01794741</DOCNO>
	<brief_summary>This 3 month safety study Dymista Nasal spray child age 4 11 year allergic rhinitis</brief_summary>
	<brief_title>3 Month Safety Study Dymista Nasal Spray Fluticasone Propionate Children 4-11 Years Age With Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Male female subject ≥ 4 year &lt; 12 year , inclusive screen visit A history allergic rhinitis ( AR ) The parent/caregiver must provide write informed consent child must provide assent Willing able comply study requirement Require treatment Dymista Nasal Spray , base Investigator 's assessment ( base medical history , physical examination , etc . ) subject ' clinical condition , Screening Randomization Visits General good health free disease concomitant treatment could interfere interpretation study result determine investigator sponsor 's medical officer Subjects receive immunotherapy injection ( antigen desensitization ) must stable maintenance regimen least 30 day first study visit ( adjustment regimen follow brief period miss injection preclude participation ) On nasal examination , subject superficial nasal mucosal erosion , moderate nasal mucosal erosion , nasal mucosal ulceration , nasal septum perforation Nasal disease ( ) likely affect deposition intranasal medication , acute chronic sinusitis , rhinitis medicamentosa , clinically significant polyposis clinically significant nasal structural abnormality Nasal surgery sinus surgery within previous year The use investigational drug within 30 day prior Visit 1 . No investigational product permit use conduct study Presence hypersensitivity azelastine hydrochloride and/or fluticasone propionate drug similar azelastine hydrochloride and/or fluticasone propionate Respiratory tract infection within two week prior Visit 1 . Subjects significant pulmonary disease include asthma . Subjects intermittent asthma require shortacting inhaled bronchodilator ( often twice per week ) nocturnal awaken result asthma eligible enrollment Chronic obstructive sleep apnea syndrome ( clinical diagnosis ) Existence surgical medical condition , opinion investigator sponsor 's medical monitor , might significantly alter absorption , distribution , metabolism , excretion study drug might significantly affect subject 's ability complete trial Clinically relevant abnormal physical finding laboratory result , opinion investigator , would interfere objective study may preclude compliance study procedure Family member research center private practice personnel directly involve study exclude Members family enroll study time . Subjects use medication therapy could interfere safety evaluation ( see Sections 4.0 5.0 ) proper washouts medication therapy Any behavioral condition could affect subject 's ability accurately report symptom caregiver developmental delay , attention deficit disorder , autism Positive pregnancy test female subject ≥ 9 year age Females pregnant nursing practice medically acceptable method contraception Subjects fail complete symptom diary leadin period , define miss data &gt; 50 % entry</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>